ABSTRACTAvoiding unwanted immunogenicity is of key importance in the development of therapeutic drug proteins. Animal models are of less predictive value because most of the drug proteins are recognized as foreign proteins. However, different methods have been developed to obtain immunotolerant animal models. So far, the immunotolerant animal models have been developed to assess one protein at a time and are not suitable for the assessment of combination products. Our aim was to develop an animal model for evaluating the impact of manufacturing and formulation changes on immunogenicity, suitable for both single protein and combination products. We constructed two lines of transgenic mice expressing the three human coagulation factors, II, V...
If immunized with an antigen of interest, transgenic mice with large portions of unrearranged human ...
Well-developed mouse models are important for understanding the pathogenesis and progression of immu...
Purpose Human factor VIIa (FVIIa) is commonly used as bypassing therapy to treat bleeding episodes i...
ABSTRACT: Avoiding unwanted immunogenicity is of key importance in the development of therapeutic dr...
The development of antibodies after administration of pharmaceutical proteins is not only of academi...
The development of anti-drug-antibodies (ADA) to biopharmaceuticals, e.g. recombinant proteins inclu...
Animal antisera were the first proteins introduced in medicine more than a century ago, followed in ...
The success of clinical and commercial therapeutic proteins is rapidly increasing, but their potenti...
Reporter proteins have become an indispensable tool in biomedical research. However, exogenous intro...
With the increase in knowledge resulting from the sequencing of the human genome, the genetic basis ...
Therapeutic proteins have become an important class of drugs. One of those proteins currently on the...
Our understanding of the molecular pathways that control immune responses, particularly immunomodula...
The impressive progress in transgenic techniques in mice within the past ten years has opened up val...
Mouse models are commonly used to assess the immunogenicity of therapeutic proteins and to investiga...
Interferon beta may induce antibodies in multiple sclerosis patients and the incidence of immunogeni...
If immunized with an antigen of interest, transgenic mice with large portions of unrearranged human ...
Well-developed mouse models are important for understanding the pathogenesis and progression of immu...
Purpose Human factor VIIa (FVIIa) is commonly used as bypassing therapy to treat bleeding episodes i...
ABSTRACT: Avoiding unwanted immunogenicity is of key importance in the development of therapeutic dr...
The development of antibodies after administration of pharmaceutical proteins is not only of academi...
The development of anti-drug-antibodies (ADA) to biopharmaceuticals, e.g. recombinant proteins inclu...
Animal antisera were the first proteins introduced in medicine more than a century ago, followed in ...
The success of clinical and commercial therapeutic proteins is rapidly increasing, but their potenti...
Reporter proteins have become an indispensable tool in biomedical research. However, exogenous intro...
With the increase in knowledge resulting from the sequencing of the human genome, the genetic basis ...
Therapeutic proteins have become an important class of drugs. One of those proteins currently on the...
Our understanding of the molecular pathways that control immune responses, particularly immunomodula...
The impressive progress in transgenic techniques in mice within the past ten years has opened up val...
Mouse models are commonly used to assess the immunogenicity of therapeutic proteins and to investiga...
Interferon beta may induce antibodies in multiple sclerosis patients and the incidence of immunogeni...
If immunized with an antigen of interest, transgenic mice with large portions of unrearranged human ...
Well-developed mouse models are important for understanding the pathogenesis and progression of immu...
Purpose Human factor VIIa (FVIIa) is commonly used as bypassing therapy to treat bleeding episodes i...